5:17 PM
 | 
Oct 04, 2013
 |  BC Extra  |  Company News

J&J in trio of European deals

Johnson & Johnson (NYSE:JNJ) announced three deals, including a deal in which Effimune S.A.S. (Nantes, France) granted J&J an exclusive option to FR104, a human mAb CD28 antagonist in preclinical development for autoimmune...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >